These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 10517605

  • 1. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum.
    Guillemin I, Sougakoff W, Cambau E, Revel-Viravau V, Moreau N, Jarlier V.
    Microbiology (Reading); 1999 Sep; 145 ( Pt 9)():2527-2532. PubMed ID: 10517605
    [Abstract] [Full Text] [Related]

  • 2. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
    Revel-Viravau V, Truong QC, Moreau N, Jarlier V, Sougakoff W.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2054-61. PubMed ID: 8878580
    [Abstract] [Full Text] [Related]

  • 3. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.
    Guillemin I, Jarlier V, Cambau E.
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2084-8. PubMed ID: 9687411
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J, Okamoto S, Takahata M, Nishino T.
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD, Martin BA.
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME.
    Am J Med; 1989 Nov 30; 87(5A):2S-8S. PubMed ID: 2574005
    [Abstract] [Full Text] [Related]

  • 16. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.
    Heifets LB, Lindholm-Levy PJ.
    Antimicrob Agents Chemother; 1990 May 30; 34(5):770-4. PubMed ID: 2113793
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
    Kaur D, Khuller GK.
    Int J Antimicrob Agents; 2001 Jan 30; 17(1):51-5. PubMed ID: 11137649
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.